StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3032% below fair value
$10.71+0.02 (+0.19%)

Close on Nov 20, 2026Market cap $1.25BP/E –Yield –

NovoCure gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

NovoCure's gross profit for the twelve months ending Sep 30, 2026 was $558.67M, up 15.4% year over year. For fiscal 2025 it was $488.47M, up 4.4% from the year before. Over ten years it grew 44.3% a year on average. The highest annual figure on record is $488.47M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$488.47M+4.4%
FY2024Dec 31, 2024$468.04M+22.8%
FY2023Dec 31, 2023$381.06M-9.9%
FY2022Dec 31, 2022$422.97M+0.7%
FY2021Dec 31, 2021$420.15M+8.3%
FY2020Dec 31, 2020$387.87M+47.6%
FY2019Dec 31, 2019$262.71M+56.4%
FY2018Dec 31, 2018$168.02M+38.4%
FY2017Dec 31, 2017$121.42M+231.7%
FY2016Dec 31, 2016$36.61M+193.4%
FY2015Dec 31, 2015$12.48M+128.8%
FY2014Dec 31, 2014$5.45M+63.0%
FY2013Dec 31, 2013$3.35M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$148.87M+21.6%
Q2 FY2026Jun 30, 2026$142.48M+21.4%
Q1 FY2026Mar 31, 2026$135.13M+16.0%
Q4 FY2025Dec 31, 2025$132.19M+3.4%
Q3 FY2025Sep 30, 2025$122.48M+2.3%
Q2 FY2025Jun 30, 2025$117.33M+1.4%
Q1 FY2025Mar 31, 2025$116.47M+11.1%
Q4 FY2024Dec 31, 2024$127.80M+26.2%
Q3 FY2024Sep 30, 2024$119.72M+25.7%
Q2 FY2024Jun 30, 2024$115.70M+25.7%
Q1 FY2024Mar 31, 2024$104.81M+13.2%
Q4 FY2023Dec 31, 2023$101.23M+1.7%
Q3 FY2023Sep 30, 2023$95.23M-5.9%
Q2 FY2023Jun 30, 2023$92.03M-18.1%
Q1 FY2023Mar 31, 2023$92.57M-15.7%
Q4 FY2022Dec 31, 2022$99.54M-3.8%
Q3 FY2022Sep 30, 2022$101.25M-2.1%
Q2 FY2022Jun 30, 2022$112.36M+7.1%
Q1 FY2022Mar 31, 2022$109.82M+1.4%
Q4 FY2021Dec 31, 2021$103.53M-10.6%
Q3 FY2021Sep 30, 2021$103.40M-0.8%
Q2 FY2021Jun 30, 2021$104.92M+16.0%
Q1 FY2021Mar 31, 2021$108.31M+40.1%
Q4 FY2020Dec 31, 2020$115.82M+55.6%
Q3 FY2020Sep 30, 2020$104.27M+50.8%
Q2 FY2020Jun 30, 2020$90.45M+37.9%
Q1 FY2020Mar 31, 2020$77.33M+44.6%
Q4 FY2019Dec 31, 2019$74.45M+59.6%
Q3 FY2019Sep 30, 2019$69.16M+51.0%
Q2 FY2019Jun 30, 2019$65.61M+57.4%
Q1 FY2019Mar 31, 2019$53.50M+57.9%
Q4 FY2018Dec 31, 2018$46.65M+22.7%
Q3 FY2018Sep 30, 2018$45.81M+31.0%
Q2 FY2018Jun 30, 2018$41.68M+65.2%
Q1 FY2018Mar 31, 2018$33.89M+46.0%
Q4 FY2017Dec 31, 2017$38.02M+97.3%
Q3 FY2017Sep 30, 2017$34.96M–
Q2 FY2017Jun 30, 2017$25.22M–
Q1 FY2017Mar 31, 2017$23.22M–
Q4 FY2016Dec 31, 2016$19.27M–

More NovoCure figures

See a number that looks wrong?